Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma

Press/Media: Press / Media

PeriodNov 17 2014

Media coverage

42

Media coverage

  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletBusinessWeek
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletReuters
    CountryUnited Kingdom
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletIndividual.com
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletPettinga Financial Advisors
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletA.M. Best
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletSecurities Technology Monitor
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletCEOWorld Magazine
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletRCL Advisors
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletSearchBug
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletFranklin Credit Management Corporation
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletVision Monday
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletCrawford Financial Planning
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletFat Pitch Financials
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletIndustrial Info Financials
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletMarket Pulse Navigator
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletWall Street Select
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletFinancial Content
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletMoneyShow.com
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletBioSpace
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletRenewable Energy World
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletReliance Trust
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletNasdaq
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletTown Hall
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletStreet Sweeper
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletWall Street Business Network
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletFreshnews.com
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletStockwatch
    CountryCanada
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletTamar Securities
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletI Stock Analyst
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletStock Nod
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletU-T San Diego
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletWGNT
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletWGNT
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletAsk.com
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletWGNT
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletWGNT
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletWGNT
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletWGNT
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletMarketWired
    CountryCanada
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletStockboard Media Inc.
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletBusinessPress24
    CountryGermany
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outletStockhouse Bulletin Boards
    CountryCanada
    Date11/17/14
    PersonsAndrew Brenner